CombiGene raised 75MSEK through rights issue

This week, CombiGene announced the outcome of a rights issue, which was was resolved by the board of directors on 8 March 2021 based on the authorisation from the annual general meeting held on 29 June 2020. CombiGene will receive proceeds of approximately 75 MSEK before issue costs, which means that the company can advance its preclinical program for CG01 and in vivo studies in the lipodystrophy project CGT2. CEO Jan Nilsson joined BioStock for a comment on the financing round.